Li Zhanguo

[Expert Profile] Li Zhanguo, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in rheumatoid arthritis in China, working in the Department of Rheumatology, Peking University People's Hospital. He has long been dedicated to the clinical diagnosis, treatment, and translational research of rheumatoid arthritis and refractory rheumatic diseases, and is an important leading figure in rheumatology in China.

[Education & Career] Professor Li Zhanguo graduated from Beijing Medical University (now Peking University Health Science Center), completed systematic clinical training at Peking University People's Hospital, and further studied at famous international rheumatology centers, systematically mastering cutting-edge international rheumatic disease diagnosis and treatment and research methods. He has long served as Director of the Rheumatology Department at Peking University People's Hospital, holding important academic positions including Chair of the Rheumatology Branch of the Chinese Medical Association and Chair of the Clinical Immunology Branch of the Chinese Immunological Society. He has presided over major projects including key grants from the National Natural Science Foundation of China and the "973" Program, and is a representative leader in the field of rheumatology in China.

[Areas of Expertise] Professor Li specializes in precise diagnosis and standardized treatment of rheumatoid arthritis, comprehensive management of refractory rheumatic diseases, and the diagnosis and treatment of various rheumatic diseases such as systemic lupus erythematosus and Sjogren's syndrome. He has extensive experience in treat-to-target (T2T) approaches for rheumatoid arthritis and individualized application of novel targeted therapies such as biologics and JAK inhibitors. He excels at managing "refractory rheumatoid patients who fail multiple medications," helping numerous patients achieve clinical remission, prevent joint destruction, and restore working capacity.

[Academic Achievements & Industry Contributions] Professor Li has led multiple large-scale Chinese rheumatoid arthritis cohort studies and multi-center clinical trials, systematically evaluating the efficacy and safety of novel targeted therapies in Chinese patients, with findings published in top international rheumatology journals. He has led the development of Chinese rheumatoid arthritis diagnosis and treatment guidelines and expert consensus statements, actively advocated for "treat-to-target" and "early standardized treatment" concepts, promoted the construction of rheumatic disease clinical research systems and biobanks, and trained a large number of rheumatology professionals, making outstanding contributions to improving Chinese rheumatoid arthritis care standards.

[Clinical Practice & Outstanding Contributions] Professor Li has long held dedicated rheumatoid arthritis clinics, cumulatively treating tens of thousands of patients with rheumatoid arthritis and various rheumatic conditions, with annual outpatient volume ranking among the highest nationwide. Leading his team, he has established a comprehensive whole-course management system for rheumatoid arthritis, helping countless patients overcome joint pain and regain self-care ability. He has received multiple national and industry honors, and has been invited to deliver keynote reports at international academic conferences on multiple occasions. He is an important representative of Chinese rheumatology on the international stage, and is deeply loved by patients and peers alike.

[Honors & Reputation] Professor Li Zhanguo holds multiple academic positions including Chair of the Rheumatology Branch of the Chinese Medical Association and Director of the Rheumatology Department at Peking University People's Hospital. He has presided over national-level projects including the National Key R&D Program and key grants from the National Natural Science Foundation of China, and is an authoritative expert in the field of rheumatology and immunology in China. He has profound expertise in precise diagnosis and treat-to-target treatment of rheumatoid arthritis and refractory rheumatic diseases. He has led international multi-center clinical research, bringing Chinese rheumatology clinical research to internationally advanced levels, with findings published in top international journals and receiving multiple science and technology awards. He has actively promoted the standardized rheumatic disease diagnosis and treatment system, trained a large number of rheumatology professionals, and is deeply trusted by patients and respected by peers alike.